PE20100092A1 - Inmunoglobulina con dominio variable dual y usos de la misma - Google Patents
Inmunoglobulina con dominio variable dual y usos de la mismaInfo
- Publication number
- PE20100092A1 PE20100092A1 PE2009000768A PE2009000768A PE20100092A1 PE 20100092 A1 PE20100092 A1 PE 20100092A1 PE 2009000768 A PE2009000768 A PE 2009000768A PE 2009000768 A PE2009000768 A PE 2009000768A PE 20100092 A1 PE20100092 A1 PE 20100092A1
- Authority
- PE
- Peru
- Prior art keywords
- tnf
- immunoglobulin
- seq
- sequence
- variable domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/545—IL-1
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
Abstract
SE REFIERE A UNA INMUNOGLOBULINA CON DOMINIO VARIABLE DUAL QUE CONTIENE UNA PROTEINA DE UNION QUE COMPRENDE CADENAS POLIPEPTIDICAS TALES COMO: I) VD1-(X1)n-VD2-C-(X2)n DONDE VD1 Y VD2 SON EL PRIMER Y SEGUNDO DOMINIO VARIABLE DE LA CADENA PESADA RESPECTIVAMENTE Y COMPRENDEN UNA SECUENCIA DE AMINOACIDOS SELECCIONADA DE LA SEQ ID Nº 28, 30, 32, 34, 36, 38, 40, 42, ENTRE OTROS; C ES UN DOMINIO CONSTANTE DE LA CADENA PESADA; X1 ES UN CONECTOR DIFERENTE DE CH1; X2 ES LA REGION Fc SELECCIONADA DE IgG1, IgG2, IgG3, ENTRE OTROS, Y DONDE X1 O X2 ES UNA SECUENCIA DE AMINOACIDOS SELECCIONADA DE LA SEQ ID Nº 1-26; n ES 0 O 1; II) VD1-(X1)n-VD2-C-(X2)n DONDE VD1 Y VD2 SON EL PRIMER Y SEGUNDO DOMINIO VARIABLE DE LA CADENA LIVIANA RESPECTIVAMENTE Y COMPRENDEN UNA SECUENCIA DE AMINOACIDOS SELECCIONADA DE LA SEQ ID Nº 29, 31, 33, 35, 37, 39, 41, 43, ENTRE OTROS; C ES UN DOMINIO CONSTANTE DE LA CADENA LIVIANA; X1 ES UN CONECTOR DIFERENTE DE CH1; X2 NO COMPRENDE UNA REGION Fc; n ES 0 O 1. DICHA PROTEINA DE UNION ES CAPAZ DE UNIR UN PAR DE ANTIGENOS TALES COMO TNF Y IL-17A, TNF Y RANKL, TNF Y VEGF, TNF Y IL-6, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION DE DICHA INMUNOGLOBULINA Y A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE ARTRITIS, LUPUS ERITEMATOSO SISTEMICO, ASMA, PSORIASIS, SINDROME NEFROTICO
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13081708P | 2008-06-03 | 2008-06-03 | |
US19717208P | 2008-10-23 | 2008-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20100092A1 true PE20100092A1 (es) | 2010-03-12 |
Family
ID=41398845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2009000768A PE20100092A1 (es) | 2008-06-03 | 2009-06-03 | Inmunoglobulina con dominio variable dual y usos de la misma |
Country Status (25)
Country | Link |
---|---|
US (3) | US9035027B2 (es) |
EP (2) | EP2297209A4 (es) |
JP (1) | JP2011523853A (es) |
KR (1) | KR20110016958A (es) |
CN (1) | CN102112495A (es) |
AR (1) | AR072001A1 (es) |
AU (1) | AU2009256250B2 (es) |
BR (1) | BRPI0913406A2 (es) |
CA (1) | CA2726087A1 (es) |
CL (1) | CL2010001427A1 (es) |
CO (1) | CO6331347A2 (es) |
CR (1) | CR11837A (es) |
DO (1) | DOP2010000368A (es) |
EC (1) | ECSP10010644A (es) |
IL (1) | IL209529A0 (es) |
MX (1) | MX2010013239A (es) |
NO (1) | NO20101692A1 (es) |
NZ (1) | NZ589434A (es) |
PE (1) | PE20100092A1 (es) |
RU (1) | RU2010153580A (es) |
SG (1) | SG191639A1 (es) |
TW (1) | TW201008580A (es) |
UY (1) | UY31862A (es) |
WO (1) | WO2009149189A2 (es) |
ZA (1) | ZA201008560B (es) |
Families Citing this family (206)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1133558B2 (en) | 1998-11-27 | 2016-04-13 | UCB Pharma S.A. | Compositions and methods for increasing bone mineralization |
EP1355666B1 (en) | 2000-12-22 | 2012-06-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of repulsive guidance molecule (RGM) and its modulators |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
US20090215992A1 (en) * | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
CA2624562A1 (en) | 2005-09-30 | 2007-04-12 | Abbott Gmbh & Co. Kg | Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use |
CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
SG190572A1 (en) | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
KR20110016959A (ko) | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
RU2011104348A (ru) * | 2008-07-08 | 2012-08-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение |
US20100041133A1 (en) * | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
US8211656B2 (en) * | 2008-08-13 | 2012-07-03 | The Invention Science Fund I, Llc | Biological targeting compositions and methods of using the same |
US20110070154A1 (en) * | 2008-08-13 | 2011-03-24 | Hyde Roderick A | Artificial cells |
US20100042072A1 (en) * | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
US20100040546A1 (en) * | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
EP2401297A1 (en) * | 2009-02-24 | 2012-01-04 | Glaxo Group Limited | Antigen-binding constructs |
EP2401298A1 (en) * | 2009-02-24 | 2012-01-04 | Glaxo Group Limited | Antigen-binding constructs |
PE20160651A1 (es) | 2009-03-05 | 2016-07-24 | Abbvie Inc | Proteinas de union a il-17 |
KR20110124368A (ko) * | 2009-04-07 | 2011-11-16 | 로슈 글리카트 아게 | 이중특이적 항―erbb―2/항―c―met 항체 |
NZ598524A (en) | 2009-08-29 | 2014-06-27 | Abbvie Inc | Therapeutic dll4 binding proteins |
IN2012DN02737A (es) | 2009-09-01 | 2015-09-11 | Abbott Lab | |
US9493578B2 (en) * | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
WO2011047262A2 (en) | 2009-10-15 | 2011-04-21 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
WO2011068927A2 (en) * | 2009-12-04 | 2011-06-09 | Abbott Laboratories | 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF |
US9175075B2 (en) | 2009-12-08 | 2015-11-03 | AbbVie Deutschland GmbH & Co. KG | Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein |
CN105037543B (zh) * | 2010-03-02 | 2020-11-03 | Abbvie 公司 | 治疗性dll4结合蛋白 |
WO2011112566A2 (en) * | 2010-03-11 | 2011-09-15 | Abbott Laboratories | Basigin binding proteins |
CA2795734A1 (en) | 2010-04-07 | 2011-10-13 | Abbvie Inc. | Tnf-.alpha. binding proteins |
WO2011131746A2 (en) * | 2010-04-20 | 2011-10-27 | Genmab A/S | Heterodimeric antibody fc-containing proteins and methods for production thereof |
LT2571532T (lt) | 2010-05-14 | 2017-08-10 | Abbvie Inc. | Il-1 surišantys baltymai |
PT3195880T (pt) | 2010-05-14 | 2020-02-21 | Amgen Inc | Formulações de anticorpos antiesclerostina de concentração elevada |
AU2016222339B2 (en) * | 2010-05-14 | 2017-11-23 | Abbvie Inc. | IL-1 binding proteins |
JP2013539353A (ja) * | 2010-06-24 | 2013-10-24 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリンおよびその使用 |
US8637641B2 (en) | 2010-07-29 | 2014-01-28 | Xencor, Inc. | Antibodies with modified isoelectric points |
AU2014246410B2 (en) * | 2010-08-03 | 2016-06-16 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
AR082461A1 (es) * | 2010-08-03 | 2012-12-12 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
KR20130139884A (ko) | 2010-08-26 | 2013-12-23 | 애브비 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
EP2635694A4 (en) * | 2010-11-02 | 2015-11-11 | Abbott Lab | VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF |
AU2014259523B2 (en) * | 2010-11-05 | 2016-02-04 | Novartis Ag | Methods of treating psoriatic arthritis using IL-17 antagonists |
CA2813849C (en) | 2010-11-05 | 2021-06-15 | Novartis Ag | Secukinumab for use in the treatment of ankylosing spondylitis |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
CN103619879A (zh) | 2010-12-01 | 2014-03-05 | 奥尔德生物控股有限责任公司 | 抗ngf组合物及其用途 |
CA2821976A1 (en) * | 2010-12-21 | 2012-09-13 | Abbvie Inc. | Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use |
DK2663579T3 (en) | 2011-01-14 | 2017-07-31 | Univ California | THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF |
BR112013020259A2 (pt) * | 2011-02-08 | 2018-05-15 | Abbvie Inc | tratamento de osteoartrite e dores |
MX2013010011A (es) * | 2011-03-01 | 2014-10-24 | Amgen Inc | Agentes de unión biespecífica. |
CA2830254C (en) | 2011-03-16 | 2019-09-10 | Amgen Inc. | Fc variants |
KR20140018315A (ko) | 2011-03-25 | 2014-02-12 | 암젠 인크 | 항스클러로스틴 항체 결정 및 이의 제제 |
AU2012245205B2 (en) | 2011-04-21 | 2017-06-01 | The Regents Of The University Of California, A California Corporation | Compositions and methods for the treatment of neuromyelitis optica |
EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
WO2012163521A1 (en) * | 2011-05-27 | 2012-12-06 | Dutalys | Removal of monomeric targets |
DK2739311T3 (en) | 2011-08-04 | 2018-04-23 | Amgen Inc | Method of treating bone slit defects |
JP6159724B2 (ja) * | 2011-08-23 | 2017-07-05 | ロシュ グリクアート アーゲー | T細胞活性化抗原に対して特異的な二重特異性抗体及び腫瘍抗原および使用方法 |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
BR112014009810A2 (pt) * | 2011-10-24 | 2017-04-25 | Abbvie Inc | imunoligantes biespecíficos dirigidos contra tnf e il-17 |
CN104093739A (zh) | 2011-10-24 | 2014-10-08 | 艾伯维公司 | 针对tnf的免疫结合剂 |
TW201323440A (zh) * | 2011-10-24 | 2013-06-16 | Abbvie Inc | 抗骨硬化素(sclerostin)之免疫結合物 |
CN104302665B (zh) | 2011-12-21 | 2019-04-23 | 安姆根有限公司 | 与新生儿Fc受体的结合增强的变体Fc多肽 |
KR20200056473A (ko) | 2011-12-28 | 2020-05-22 | 암젠 인크 | 항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법 |
EP2915818A3 (en) | 2011-12-30 | 2015-11-11 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
CA2861610A1 (en) | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual specific binding proteins directed against il-13 and/or il-17 |
SG10202006762PA (en) | 2012-01-27 | 2020-08-28 | Abbvie Deutschland | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration |
RU2620563C2 (ru) | 2012-02-01 | 2017-05-26 | Ф. Хоффманн-Ля Рош Аг | Способ детекции партнера по связыванию мультиспецифического связывающего агента |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
JP6211597B2 (ja) | 2012-05-01 | 2017-10-11 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | 新規抗体 |
KR101525919B1 (ko) * | 2012-05-11 | 2015-06-03 | 가톨릭대학교 산학협력단 | 자가면역 질환 예방 및 치료를 위한 tnfr2를 기반으로 하는 이중 항체 |
TWI609882B (zh) * | 2012-05-22 | 2018-01-01 | 必治妥美雅史谷比公司 | 雙特異性抗體及其使用方法 |
WO2013184200A1 (en) * | 2012-06-05 | 2013-12-12 | Msm Protein Technologies | Human monoclonal antibodies against human chemokine receptor ccr7 |
EP2866833B1 (en) | 2012-06-27 | 2019-05-15 | Merck Sharp & Dohme Corp. | Crystalline anti-human il-23 antibodies |
EP2869844B2 (en) | 2012-07-05 | 2023-06-21 | UCB Pharma S.A. | Treatment for bone diseases |
UY34905A (es) | 2012-07-12 | 2014-01-31 | Abbvie Inc | Proteínas de unión a il-1 |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
CA2883711A1 (en) | 2012-09-07 | 2014-03-13 | The Governors Of The University Of Alberta | Methods and compositions for diagnosis of inflammatory liver disease |
WO2014055967A2 (en) * | 2012-10-05 | 2014-04-10 | Neotope Biosciences Limited | Compositions and methods for treating diseases of protein aggregation involving ic3b deposition |
US9217042B2 (en) * | 2012-10-23 | 2015-12-22 | Abbott Cardiovascular Systems Inc. | Method of reducing MACE in diabetic patients subsequent to stent placement |
KR20210111353A (ko) | 2012-11-01 | 2021-09-10 | 애브비 인코포레이티드 | 항-vegf/dll4 이원 가변 도메인 면역글로불린 및 이의 용도 |
SG10201802044RA (en) * | 2012-11-01 | 2018-05-30 | Abbvie Inc | Stable dual variable domain immunoglobulin protein formulations |
CA2891556A1 (en) | 2012-11-16 | 2014-05-22 | Novartis Ag | Use of il-1 beta binding antibodies for treating peripheral arterial disease |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
US20140154702A1 (en) * | 2012-11-30 | 2014-06-05 | Endocyte, Inc. | Methods For Treating Cancer Using Combination Therapies |
US20140212423A1 (en) | 2012-12-04 | 2014-07-31 | Abbvie, Inc. | Blood-brain barrier penetrating dual specific binding proteins |
UA117466C2 (uk) * | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
US9856319B2 (en) | 2012-12-28 | 2018-01-02 | Abbvie Inc. | Monovalent binding proteins |
WO2014106001A2 (en) | 2012-12-28 | 2014-07-03 | Abbvie, Inc. | Dual specific binding proteins having a receptor sequence |
CN103060274B (zh) * | 2012-12-28 | 2013-12-11 | 首都医科大学 | Rankl-tnf样区鼠源性单克隆抗体及其制备方法与应用 |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
AU2014205086B2 (en) | 2013-01-14 | 2019-04-18 | Xencor, Inc. | Novel heterodimeric proteins |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
AU2014207549B2 (en) | 2013-01-15 | 2018-12-06 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
EP2948475A2 (en) | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
AU2013381687A1 (en) | 2013-03-12 | 2015-09-24 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
RU2015143833A (ru) | 2013-03-15 | 2017-04-21 | Эббви Инк. | СВЯЗЫВАЮЩИЕ БЕЛКИ С ДВОЙНОЙ СПЕЦИФИЧНОСТЬЮ, НАПРАВЛЕННЫЕ ПРОТИВ TNFα |
US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
US10544187B2 (en) | 2013-03-15 | 2020-01-28 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
JP2016522793A (ja) | 2013-03-15 | 2016-08-04 | アッヴィ・インコーポレイテッド | IL−1βおよび/またはIL−17に対して指向された二重特異的結合タンパク質 |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
EP2970484B2 (en) | 2013-03-15 | 2022-09-21 | Amgen Inc. | Heterodimeric bispecific antibodies |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
WO2014182658A1 (en) | 2013-05-06 | 2014-11-13 | Abbvie Inc. | Compositions for cell culture and methods of using the same |
US9506053B2 (en) | 2013-08-01 | 2016-11-29 | Abbvie Inc. | Methods of selecting biologic-producing cell lines by next generation sequencing |
WO2015048272A1 (en) | 2013-09-25 | 2015-04-02 | Amgen Inc. | V-c-fc-v-c antibody |
EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
AU2014331584A1 (en) | 2013-10-06 | 2016-04-28 | Abbvie Inc. | Dual specific binding proteins directed against immune cell receptors and TLR signaling autoantigens |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
EP3062818B1 (en) * | 2013-11-01 | 2019-09-11 | IBC Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
MX2016008667A (es) | 2013-12-30 | 2017-02-02 | Epimab Biotherapeutics Inc | Inmunoglobulina con fab en tandem y usos de esta. |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
WO2015114150A1 (en) | 2014-02-02 | 2015-08-06 | Medimmune Limited | Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain |
EP3725311A1 (en) | 2014-02-10 | 2020-10-21 | Respivant Sciences GmbH | Methods for the treatment of lung diseases with mast cell stabilizers |
SI3104853T1 (sl) | 2014-02-10 | 2020-03-31 | Respivant Sciences Gmbh | Zdravljenje s stabilizatorji mastocitov za sistemske motnje |
RU2732226C2 (ru) * | 2014-03-17 | 2020-09-14 | Мицубиси Танабе Фарма Корпорейшн | Конъюгаты антитело-финомер |
AP2016009475A0 (en) | 2014-03-28 | 2016-09-30 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3 |
NO2776305T3 (es) | 2014-04-23 | 2018-01-27 | ||
CN104004080A (zh) * | 2014-06-06 | 2014-08-27 | 首都医科大学 | 靶向于RANKL和TNF-α的人源化抗体及其应用 |
WO2015191934A2 (en) | 2014-06-11 | 2015-12-17 | Abbvie Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
EP3164194B1 (en) | 2014-07-03 | 2021-11-24 | Yale University | Dickkopf2 (dkk2) inhibition suppresses tumor formation |
CN107206071A (zh) | 2014-09-13 | 2017-09-26 | 诺华股份有限公司 | Alk抑制剂的联合疗法 |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US11471487B2 (en) | 2014-10-31 | 2022-10-18 | The Trustees Of The University Of Pennsylvania | Compositions and methods of stimulating and expanding T cells |
AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
MX2017006918A (es) | 2014-11-26 | 2018-01-25 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y cd38. |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
PE20171324A1 (es) | 2014-11-26 | 2017-09-11 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales |
WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
WO2016153838A1 (en) * | 2015-03-20 | 2016-09-29 | Full Spectrum Genetics, Inc. | Novel anti-tnfa binding compounds and uses thereof |
WO2016160976A2 (en) | 2015-03-30 | 2016-10-06 | Abbvie Inc. | Monovalent tnf binding proteins |
CN108472360B (zh) | 2015-04-10 | 2023-01-17 | 阿迪马布有限责任公司 | 从亲代同源二聚抗体种类中纯化异源二聚多特异性抗体的方法 |
US10526404B2 (en) | 2015-04-29 | 2020-01-07 | Institute For Research In Biomedicine | Multispecific anti GM-CSF antibodies |
CN107709355B (zh) | 2015-05-04 | 2021-09-14 | 阿珀吉尼科斯股份公司 | 单链cd40受体激动剂蛋白 |
EP3298037B1 (en) * | 2015-05-18 | 2019-09-11 | Eli Lilly and Company | Anti-dkk-1-anti-rankl bispecific antibody compounds |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
US10238625B2 (en) | 2015-08-07 | 2019-03-26 | Respivant Sciences Gmbh | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
WO2017027402A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
JP2017057201A (ja) * | 2015-09-16 | 2017-03-23 | 田辺三菱製薬株式会社 | 抗体−フィノマー複合体を含む医薬組成物 |
CN108430492B (zh) | 2015-10-23 | 2022-05-03 | 阿珀吉科吉尼科斯股份公司 | 单链cd27受体激动剂蛋白 |
WO2017068185A1 (en) | 2015-10-23 | 2017-04-27 | Apogenix Ag | Single-chain gitr-receptor agonist proteins |
WO2017074878A1 (en) | 2015-10-25 | 2017-05-04 | Sanofi | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection |
CA3003511A1 (en) | 2015-10-28 | 2017-05-04 | Apogenix Ag | Single-chain tl1a receptor agonist proteins |
JP6983371B2 (ja) * | 2015-11-17 | 2021-12-17 | スーヂョウ サンケイディア バイオファーマスーティカルズ カンパニー リミテッド | 抗pd−l1抗体、その抗原結合フラグメントおよびその医療用途 |
WO2017085693A1 (en) | 2015-11-19 | 2017-05-26 | AbbVie Deutschland GmbH & Co. KG | Reporter gene assay methods for identifying and analyzing multi-specific binding proteins |
EP3387013B1 (en) | 2015-12-07 | 2022-06-08 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
BR112018015485A2 (pt) | 2016-02-06 | 2018-12-18 | Epimab Biotherapeutics Inc | imunoglobulina fabs-in-tandem e usos da mesma |
SG10202007520WA (en) | 2016-03-02 | 2020-09-29 | Eisai R&D Man Co Ltd | Eribulin-based antibody-drug conjugates and methods of use |
GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
RS64771B1 (sr) * | 2016-04-13 | 2023-11-30 | Sanofi Sa | Trispecifični i/ili trovalentni vezujući proteini |
US10604586B2 (en) | 2016-05-09 | 2020-03-31 | Industrial Technology Research Institute | Humanized monoclonal antibody and uses thereof |
RU2767357C2 (ru) | 2016-06-14 | 2022-03-17 | Ксенкор, Инк. | Биспецифические антитела-ингибиторы контрольных точек |
CA3029328A1 (en) | 2016-06-28 | 2018-01-04 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
CN110139646A (zh) | 2016-08-31 | 2019-08-16 | 瑞思皮万特科学有限责任公司 | 用于治疗由特发性肺纤维化引起的慢性咳嗽的色甘酸组合物 |
AU2017339366A1 (en) | 2016-10-07 | 2019-04-11 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of pulmonary fibrosis |
WO2018071919A1 (en) | 2016-10-14 | 2018-04-19 | Xencor, Inc. | IL15/IL15Rα HETERODIMERIC FC-FUSION PROTEINS |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
PT3443006T (pt) | 2017-03-17 | 2023-10-26 | Sanofi Sa | Proteínas de ligação triespecíficas e/ou trivalentes |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
CN111132733A (zh) | 2017-06-30 | 2020-05-08 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白 |
WO2019011167A1 (zh) * | 2017-07-12 | 2019-01-17 | 四川科伦博泰生物医药股份有限公司 | 双特异性重组蛋白 |
US11186649B2 (en) | 2017-10-10 | 2021-11-30 | Sanofi | Anti-CD38 antibodies and methods of use |
CN112272563A (zh) | 2017-11-08 | 2021-01-26 | Xencor股份有限公司 | 使用新颖抗pd-1序列的双特异性和单特异性抗体 |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
KR20200100098A (ko) | 2017-12-19 | 2020-08-25 | 젠코어 인코포레이티드 | 조작된 il-2 fc 융합 단백질 |
MX2020007444A (es) | 2018-01-12 | 2020-09-14 | Genzyme Corp | Metodos para la cuantificacion de polipeptidos. |
BR112020016551A2 (pt) | 2018-02-16 | 2020-12-22 | Abbvie Inc. | Inibidores de bcl-2 seletivos em combinação com anticorpo anti-pd-1 ou anti-pd-l1 para o tratamento de cânceres |
AU2019243595A1 (en) | 2018-03-30 | 2020-09-17 | Amgen Inc. | C-terminal antibody variants |
WO2019195623A2 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
KR20210003814A (ko) | 2018-04-18 | 2021-01-12 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질 |
JP2021521784A (ja) | 2018-04-18 | 2021-08-30 | ゼンコア インコーポレイテッド | IL−15/IL−15RaFc融合タンパク質とPD−1抗原結合ドメインを含むPD−1標的化ヘテロダイマー融合タンパク質およびそれらの使用 |
AU2019264029A1 (en) | 2018-04-30 | 2020-11-19 | Takeda Pharmaceutical Company Limited | Cannabinoid receptor type 1 (CB1) binding proteins and uses thereof |
WO2020072821A2 (en) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
AU2019357467A1 (en) | 2018-10-09 | 2021-05-27 | Sanofi | Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection |
MX2021010390A (es) | 2019-03-01 | 2021-11-17 | Xencor Inc | Anticuerpos heterodimericos que se unen a enpp3 y cd3. |
US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
KR102323342B1 (ko) * | 2019-04-26 | 2021-11-08 | 주식회사 와이바이오로직스 | IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체 |
EP3985022A4 (en) * | 2019-06-14 | 2023-08-02 | ABL Bio, Inc. | BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ITS USE |
WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
JP2020162622A (ja) * | 2020-06-25 | 2020-10-08 | インスティテュート フォー リサーチ イン バイオメディシン | 多重特異性抗体によるサイトカインの非常に強力な中和およびその利用 |
WO2022040482A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
IL305736A (en) | 2021-03-09 | 2023-11-01 | Xencor Inc | Heterodimeric antibodies that bind CD3 and CLDN6 |
EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
CN117285643A (zh) * | 2022-06-16 | 2023-12-26 | 清华大学 | 一种相变调节套件及其用途 |
Family Cites Families (399)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2128208A (en) | 1937-02-27 | 1938-08-23 | Du Pont | Alkoxy derivatives of methacrylic acid esters and method of producing them |
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
EP0092918B1 (en) | 1982-04-22 | 1988-10-19 | Imperial Chemical Industries Plc | Continuous release formulations |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
DE3590766C2 (es) | 1985-03-30 | 1991-01-10 | Marc Genf/Geneve Ch Ballivet | |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
ATE111083T1 (de) | 1986-10-22 | 1994-09-15 | Abbott Lab | Chemilumineszierende acridinium- und phenantridiniumsalze. |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5006309A (en) | 1988-04-22 | 1991-04-09 | Abbott Laboratories | Immunoassay device with liquid transfer between wells by washing |
US5089424A (en) | 1988-06-14 | 1992-02-18 | Abbott Laboratories | Method and apparatus for heterogeneous chemiluminescence assay |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
EP1892296A1 (en) | 1988-09-02 | 2008-02-27 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
US5241070A (en) | 1988-09-26 | 1993-08-31 | Ciba Corning Diagnostics Corp. | Nucleophilic polysubstituted aryl acridinium esters and uses thereof |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
SE462454B (sv) | 1988-11-10 | 1990-06-25 | Pharmacia Ab | Maetyta foer anvaendning i biosensorer |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5063081A (en) | 1988-11-14 | 1991-11-05 | I-Stat Corporation | Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
AU652539B2 (en) | 1989-05-16 | 1994-09-01 | Medical Research Council | Co-expression of heteromeric receptors |
CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
AU6430190A (en) | 1989-10-10 | 1991-05-16 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
EP0550436A1 (en) | 1989-11-06 | 1993-07-14 | Alkermes Controlled Therapeutics, Inc. | Protein microspheres and methods of using them |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
JPH05506357A (ja) | 1990-05-25 | 1993-09-22 | ルミニス ピーティーワイ リミテッド | 酵母株同定用マーカー |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
CA2048302A1 (en) | 1990-08-15 | 1992-02-16 | Victoria P. Meucci | Solubilization reagent for biological test samples |
US5135875A (en) | 1990-08-15 | 1992-08-04 | Abbott Laboratories | Protein precipitation reagent |
AU8505191A (en) | 1990-08-24 | 1992-03-17 | Ixsys, Inc. | Methods of synthesizing oligonucleotides with random codons |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5780279A (en) | 1990-12-03 | 1998-07-14 | Genentech, Inc. | Method of selection of proteolytic cleavage sites by directed evolution and phagemid display |
ATE177782T1 (de) | 1990-12-20 | 1999-04-15 | Ixsys Inc | Optimierung von bindenden proteinen |
JP4146512B2 (ja) | 1991-03-01 | 2008-09-10 | ダイアックス コープ. | 小型タンパク質 |
HU219537B (hu) | 1991-03-06 | 2001-05-28 | Merck Patent Gmbh. | Humanizált és kiméra monoklonális antitestek, azokat tartalmazó gyógyászati készítmények, az antitesteket kódoló szekvenciát tartalmazó expressziós vektorok, valamint eljárás az antitestek előállítására |
US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
DK1097945T3 (da) | 1991-03-18 | 2007-11-05 | Univ New York | Monoklonale og kimære antistoffer, der er specifikke for human tumornekrosefaktor |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
RU2139351C1 (ru) | 1991-04-25 | 1999-10-10 | Чугаи Сейяку Кабусики Кайся | Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности |
DE69232706T2 (de) | 1991-05-01 | 2002-11-28 | Jackson H M Found Military Med | Verfahren zur behandlung infektiöser respiratorischer erkrankungen |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
CA2069530A1 (en) | 1991-06-03 | 1992-12-04 | Cass J. Grandone | Reagent pack for immunoassays |
DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
AU2238292A (en) | 1991-06-14 | 1993-01-12 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
ES2241710T3 (es) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | Procedimiento para producir proteinas multivalentes de union a antigeno. |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
US5766886A (en) | 1991-12-13 | 1998-06-16 | Xoma Corporation | Modified antibody variable domains |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5352803A (en) | 1992-03-30 | 1994-10-04 | Abbott Laboratories | 5(6)-methyl substituted fluorescein derivatives |
CA2131727A1 (en) | 1992-03-30 | 1993-10-14 | Diana E. Clarisse | Reagents and methods for the detection and quantification of thyroxine in fluid samples |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
ATE196606T1 (de) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
WO1994018219A1 (en) | 1993-02-02 | 1994-08-18 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
WO1995001997A1 (en) * | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
EP0659766A1 (en) * | 1993-11-23 | 1995-06-28 | Schering-Plough | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
US5565352A (en) | 1993-11-24 | 1996-10-15 | Arch Development Corporation | Deubiquitinating enzyme: compositions and methods |
EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
JPH09506260A (ja) | 1993-12-10 | 1997-06-24 | アボツト・ラボラトリーズ | メトトレキサートを検出するための試薬および方法 |
GB9401182D0 (en) | 1994-01-21 | 1994-03-16 | Inst Of Cancer The Research | Antibodies to EGF receptor and their antitumour effect |
DK0744958T3 (da) | 1994-01-31 | 2003-10-20 | Univ Boston | Polyklonale antistofbiblioteker |
ZA95960B (en) | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
RU2170257C2 (ru) | 1994-03-17 | 2001-07-10 | Мерк Патент Гмбх | Анти-эфрр одноцепочечный fv, химерное анти-эфрр антитело и способ его получения, фармацевтическая композиция для лечения опухолей, средство для диагностики локализации или оценки роста опухоли |
IL109632A (en) | 1994-05-11 | 2007-03-08 | Yeda Res & Dev | Modulators of the function of tnf receptors |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
AU3272695A (en) | 1994-08-12 | 1996-03-07 | Immunomedics Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
EP0805678B1 (en) | 1995-01-05 | 2003-10-29 | THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN | Surface-modified nanoparticles and method of making and using same |
GB9504344D0 (en) | 1995-03-03 | 1995-04-19 | Unilever Plc | Antibody fragment production |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
KR100479146B1 (ko) | 1995-04-21 | 2005-05-16 | 셀 제네시스, 인코포레이티드 | 큰게놈dna결실유발법 |
DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
WO1997007788A2 (en) | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
WO1997014719A1 (en) | 1995-10-16 | 1997-04-24 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
US6331431B1 (en) | 1995-11-28 | 2001-12-18 | Ixsys, Inc. | Vacuum device and method for isolating periplasmic fraction from cells |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
BRPI9715219B8 (pt) * | 1996-02-09 | 2015-07-07 | Abbvie Biotechnology Ltd | Vetor recombinante de expressão, e célula hospedeira procariótica. |
PT885002E (pt) | 1996-03-04 | 2011-07-14 | Massachusetts Inst Technology | Materiais e métodos para aumento da internalização celular |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
NZ331688A (en) | 1996-03-28 | 2000-02-28 | Univ Johns Hopkins | Soluble divalent and multivalent heterodimeric analogs of proteins |
JP2000508892A (ja) | 1996-04-04 | 2000-07-18 | ユニリーバー・ナームローゼ・ベンノートシャープ | 多価および多特異的抗原結合タンパク |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US6986890B1 (en) | 1996-11-21 | 2006-01-17 | Kyowa Hakko Kogyo Co., Ltd. | Anti-human VEGF receptor Flt-1 monoclonal antibody |
ATE387495T1 (de) | 1996-12-03 | 2008-03-15 | Amgen Fremont Inc | Vollkommen humane antikörper die egfr binden |
CA2277801C (en) | 1997-01-16 | 2002-10-15 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
PT971946E (pt) | 1997-01-21 | 2006-11-30 | Gen Hospital Corp | Selecção de proteínas utilizando fusões arn-proteína |
US7306914B2 (en) | 1997-01-31 | 2007-12-11 | Odyssey Thera Inc. | Protein fragment complementation assays in whole animals applications to drug efficacy, ADME, cancer biology, immunology, infectious disease and gene therapy |
US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
AU743758B2 (en) | 1997-04-07 | 2002-02-07 | Genentech Inc. | Anti-VEGF antibodies |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
NZ516848A (en) | 1997-06-20 | 2004-03-26 | Ciphergen Biosystems Inc | Retentate chromatography apparatus with applications in biology and medicine |
WO1999006834A2 (en) | 1997-08-04 | 1999-02-11 | Ixsys, Incorporated | Methods for identifying ligand specific binding molecules |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
WO1999023221A2 (en) | 1997-10-27 | 1999-05-14 | Unilever Plc | Multivalent antigen-binding proteins |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
AU2978899A (en) | 1998-03-03 | 1999-09-20 | Abgenix, Inc. | Cd147 binding molecules as therapeutics |
WO1999051773A1 (en) | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Addressable protein arrays |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US6489447B1 (en) | 1998-05-06 | 2002-12-03 | Genentech, Inc. | Protein purification |
JP2002518432A (ja) | 1998-06-24 | 2002-06-25 | アドバンスト インハレーション リサーチ,インコーポレイテッド | 吸入器から放出される大多孔性粒子 |
US6406921B1 (en) | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
US20030215458A1 (en) | 1998-09-30 | 2003-11-20 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
WO2000034337A1 (en) | 1998-12-10 | 2000-06-15 | Tsukuba Research Laboratory, Toagosei Co., Ltd. | Humanized monoclonal antibodies against vascular endothelial cell growth factor |
EP2112166B1 (en) | 1998-12-23 | 2018-11-21 | Pfizer Inc. | Human monoclonal antibodies to ctla-4 |
US8003772B2 (en) | 1999-01-14 | 2011-08-23 | Martek Biosciences Corporation | Chimeric PUFA polyketide synthase systems and uses thereof |
PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
AU4025300A (en) | 1999-03-24 | 2000-10-09 | Packard Bioscience Company | Continuous porous matrix arrays |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
TR200603997T1 (tr) | 1999-03-25 | 2010-01-21 | Abbott Gmbh & Co. Kg | Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler. |
ES2420835T3 (es) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de las moléculas inmunofuncionales |
CN1119415C (zh) | 1999-06-04 | 2003-08-27 | 长春迈灵生物工程有限公司 | 抗ca125双功能基因工程抗体的克隆与表达 |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US6531580B1 (en) | 1999-06-24 | 2003-03-11 | Ixsys, Inc. | Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same |
DK2803367T3 (en) | 1999-06-25 | 2018-04-16 | Immunogen Inc | Methods of treatment using anti-ERBB antibody-maytansinoid conjugates |
AU1456101A (en) | 1999-11-03 | 2001-05-14 | Maxygen, Inc. | Antibody diversity generation |
NZ520392A (en) | 2000-02-10 | 2005-04-29 | Abbott Lab | Antibodies that bind human interleukin-18 and methods of making and using |
JP2003523407A (ja) | 2000-02-24 | 2003-08-05 | ジェネンテック・インコーポレーテッド | カスパーゼ活性化プロドラック療法 |
US7129332B2 (en) | 2000-02-25 | 2006-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof |
AU2001260153B2 (en) | 2000-03-24 | 2006-08-17 | Micromet Ag | Multifunctional polypeptides comprising a binding site to an epitope of the NKG2D receptor complex |
CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
CA2407956A1 (en) | 2000-05-03 | 2001-11-08 | Amgen Inc. | Modified peptides as therapeutic agents |
JP2003533987A (ja) | 2000-05-19 | 2003-11-18 | イス ケミカル カンパニー リミテッド | 表皮成長因子収容体に対するヒト化抗体 |
US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
WO2002000879A2 (en) | 2000-06-28 | 2002-01-03 | Glycofi, Inc. | Methods for producing modified glycoproteins |
JP4955185B2 (ja) * | 2000-06-29 | 2012-06-20 | アボット・ラボラトリーズ | 二重特異性抗体ならびに作製方法および使用方法 |
WO2002002781A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
US20090081234A1 (en) | 2000-08-07 | 2009-03-26 | George Heavner | Anti-tnf antibodies, compositions, methods and uses for treatment of depression and related conditions |
GB0020685D0 (en) * | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
US20030157643A1 (en) | 2000-08-24 | 2003-08-21 | Almond Brian D | Synthetic nucleic acids from aquatic species |
MXPA00009407A (es) | 2000-09-26 | 2004-12-08 | Mexicano Inst Petrol | Procedimiento para la preparacion de un catalizador monometalico de tipo zeolitico para la obtencion de gasolinas de alto octando mediante reformacion de naftas. |
JP2004529610A (ja) | 2000-10-13 | 2004-09-30 | ユーエイビー リサーチ ファンデーション | ヒト抗上皮増殖因子受容体一本鎖抗体 |
WO2002077029A2 (en) | 2000-11-07 | 2002-10-03 | City Of Hope | Cd19-specific redirected immune cells |
US7601692B2 (en) | 2000-11-28 | 2009-10-13 | Compugen Ltd. | MCP-1 splice variants and methods of using same |
PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
US6818392B2 (en) | 2000-12-06 | 2004-11-16 | Abbott Laboratories | Monoclonal antibodies to human immunodeficiency virus and uses thereof |
EP1345968A2 (en) | 2000-12-28 | 2003-09-24 | Altus Biologics Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
CN1854157B (zh) | 2001-01-05 | 2013-01-02 | 辉瑞大药厂 | 胰岛素样生长因子i受体的抗体 |
US7667004B2 (en) | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
WO2002097048A2 (en) | 2001-05-30 | 2002-12-05 | Centocor, Inc. | ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES |
EP2340849A1 (en) | 2001-05-30 | 2011-07-06 | Genentech, Inc. | Anti-NGF antibodies for the treatment of various disorders |
CZ200438A3 (cs) | 2001-06-13 | 2004-06-16 | Genmab A/S | Název neuveden |
JP4249013B2 (ja) | 2001-07-31 | 2009-04-02 | 佑 本庶 | Pd−1に対し特異性を有する物質 |
US20040192898A1 (en) | 2001-08-17 | 2004-09-30 | Jia Audrey Yunhua | Anti-abeta antibodies |
US7247304B2 (en) | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
US7241873B2 (en) | 2001-09-25 | 2007-07-10 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Recombinant anti-osteopontin antibody and use thereof |
EP2093286B1 (en) | 2001-10-01 | 2013-02-27 | Dyax Corporation | Multi-chain eukaryotic display vectors and uses thereof |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
WO2003039486A2 (en) | 2001-11-09 | 2003-05-15 | Idec Pharmaceuticals Corporation | Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies |
DE10156482A1 (de) | 2001-11-12 | 2003-05-28 | Gundram Jung | Bispezifisches Antikörper-Molekül |
KR20100120246A (ko) | 2001-11-14 | 2010-11-12 | 센토코 오르토 바이오테크 인코포레이티드 | 항 il-6 항체, 조성물, 방법 및 용도 |
AU2002351353A1 (en) | 2001-12-19 | 2003-09-02 | Genentech, Inc. | Stabilizing polypeptides which have been exposed to urea |
US6870034B2 (en) | 2002-02-05 | 2005-03-22 | Genentech, Inc. | Protein purification |
MXPA04007583A (es) | 2002-02-11 | 2005-04-25 | Genentech Inc | Variantes de anticuerpo con tasas mas rapidas de asociacion a antigeno. |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US7419821B2 (en) | 2002-03-05 | 2008-09-02 | I-Stat Corporation | Apparatus and methods for analyte measurement and immunoassay |
US7371383B2 (en) | 2002-04-12 | 2008-05-13 | Medimmune, Inc. | Recombinant anti-interleukin-9 antibodies |
DK1495055T3 (da) | 2002-04-18 | 2013-11-11 | Genencor Int | Produktion af funktionelle antistoffer i filamentøse svampe |
JP4319979B2 (ja) | 2002-04-26 | 2009-08-26 | ジェネンテック・インコーポレーテッド | タンパク質の非アフィニティ精製 |
US20030206898A1 (en) | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
WO2003093317A1 (fr) | 2002-04-30 | 2003-11-13 | Kyowa Hakko Kogyo Co., Ltd. | Anticorps pour facteur de croissance humain semblable a l'insuline |
US7714189B2 (en) | 2002-05-03 | 2010-05-11 | Monsanto Technology Llc | High tryptophan maize |
NZ571508A (en) | 2002-05-24 | 2010-05-28 | Schering Corp | Neutralizing human anti-IGFR antibody |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
DK2314629T4 (da) | 2002-07-18 | 2023-02-06 | Merus Nv | Rekombinant produktion af blandinger af antistoffer |
US20040018577A1 (en) | 2002-07-29 | 2004-01-29 | Emerson Campbell John Lewis | Multiple hybrid immunoassay |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
US7202343B2 (en) | 2002-08-19 | 2007-04-10 | Abgenix, Inc. | Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof |
LT1543038T (lt) | 2002-09-11 | 2017-07-10 | Genentech, Inc. | Baltymo gryninimas |
US7928215B2 (en) | 2002-11-22 | 2011-04-19 | Eisai R&D Management Co., Ltd. | Methods of screening for compounds that inhibit the biosynthesis of GPI in malaria parasites |
JP4754219B2 (ja) | 2002-12-02 | 2011-08-24 | アムジエン・フレモント・インコーポレイテツド | 腫瘍壊死因子を対象とする抗体、およびそれらの使用 |
SI1572744T1 (sl) | 2002-12-16 | 2010-09-30 | Genentech Inc | Imunoglobulinske variante in njihove uporabe |
ZA200504866B (en) | 2002-12-24 | 2006-11-29 | Rinat Neuroscience Corp | Anti-ngf antibodies and methods using same |
CA2513113A1 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
DE602004024041D1 (de) | 2003-03-05 | 2009-12-24 | Halozyme Inc | Lösliches hyaluronidase-glycoprotein (shasegp), verfahren zu seiner herstellung, verwendungen und dieses enthaltende pharmazeutische zusammensetzungen |
ES2527871T3 (es) | 2003-05-01 | 2015-02-02 | Imclone Llc | Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana |
WO2004104020A2 (en) | 2003-05-14 | 2004-12-02 | Dow Corning Corporation | Repeat sequence protein polymer active agent conjugates, methods and uses |
US20070104722A1 (en) | 2003-05-15 | 2007-05-10 | Iogenetics | Targeted biocides |
WO2004106381A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
CN103880955A (zh) | 2003-07-18 | 2014-06-25 | 安姆根有限公司 | 肝细胞生长因子的特异性结合物 |
AU2004265253B2 (en) | 2003-07-28 | 2011-09-01 | Genentech, Inc. | Reducing protein A leaching during protein A affinity chromatography |
US20050026881A1 (en) | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease |
WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
CN1871259A (zh) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | 具有改变的效应物功能的经改进的抗体和制备它的方法 |
CA2537055A1 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
US7723099B2 (en) | 2003-09-10 | 2010-05-25 | Abbott Point Of Care Inc. | Immunoassay device with immuno-reference electrode |
US7682833B2 (en) | 2003-09-10 | 2010-03-23 | Abbott Point Of Care Inc. | Immunoassay device with improved sample closure |
US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
US20050180974A1 (en) | 2003-10-24 | 2005-08-18 | Medtronic, Inc. | Extracellular TNF inhibitors for treating CNS disorders |
US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
EP1697543B1 (en) | 2003-11-21 | 2014-08-20 | ANP Technologies, Inc. | Asymmetrically branched polymer conjugates and microarray assays |
EP2221315A1 (en) | 2003-12-04 | 2010-08-25 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
JP2007517504A (ja) | 2003-12-09 | 2007-07-05 | ベントリア バイオサイエンス | 融合担体として種子貯蔵蛋白を利用する植物種子中の融合ポリペプチドの高水準発現 |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
US7297541B2 (en) | 2004-01-26 | 2007-11-20 | Monsanto Technology Llc | Genes encoding 4-hydroxyphenylpyruvate dioxygenase (HPPD) enzymes for plant metabolic engineering |
US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
AU2005249360B2 (en) | 2004-04-12 | 2011-07-21 | Medimmune, Llc | Anti-IL-9 antibody formulations and uses thereof |
CN104611245A (zh) | 2004-04-15 | 2015-05-13 | 格利科菲公司 | 在低等真核生物中产生半乳糖基化糖蛋白 |
ES2379526T3 (es) | 2004-04-30 | 2012-04-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticuerpo anti-TfR |
JP2008508858A (ja) | 2004-05-13 | 2008-03-27 | イムクローン システムズ インコーポレイティド | マクロファージ−刺激タンパク質受容体(ron)の阻害 |
CA2567272A1 (en) | 2004-05-19 | 2005-12-01 | Agrivida, Inc. | Transgenic plants expressing intein modified proteins and associated processes for bio-pharmaceutical production |
GB0412019D0 (en) | 2004-05-28 | 2004-06-30 | Novartis Ag | Organic compounds |
US7150969B2 (en) | 2004-06-04 | 2006-12-19 | Rosetta Inpharmatics Llc | Alternatively spliced isoform of acetyl-CoA carboxylase 2 (ACC2) |
EP1786918A4 (en) | 2004-07-17 | 2009-02-11 | Imclone Systems Inc | NEW BISPECIFIC ANTIBODY TETRAVALENT |
US7709611B2 (en) | 2004-08-04 | 2010-05-04 | Amgen Inc. | Antibodies to Dkk-1 |
NZ552485A (en) | 2004-08-05 | 2009-11-27 | Genentech Inc | Humanized anti-cmet antagonists |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
WO2006031370A2 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
GB0419424D0 (en) | 2004-09-02 | 2004-10-06 | Viragen Scotland Ltd | Transgene optimisation |
RS57636B1 (sr) | 2004-09-03 | 2018-11-30 | Genentech Inc | Humanizovani anti-beta7 antagonisti i njihova upotreba |
US20060067931A1 (en) * | 2004-09-25 | 2006-03-30 | Hazel Lum | Receptor for lysophosphatidylcholine in vascular endothelial cells and use thereof |
ATE497508T1 (de) | 2004-10-01 | 2011-02-15 | Max Planck Gesellschaft | Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
JP5553963B2 (ja) | 2004-10-22 | 2014-07-23 | アムジエン・インコーポレーテツド | 組換え抗体をリフォールディングする方法 |
US20060253100A1 (en) | 2004-10-22 | 2006-11-09 | Medtronic, Inc. | Systems and Methods to Treat Pain Locally |
US7423128B2 (en) | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
US20070135620A1 (en) | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
JP2008524247A (ja) | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | 認知の改善における使用のためのアミロイドβ抗体 |
KR101017301B1 (ko) | 2004-12-21 | 2011-02-28 | 메드임뮨 리미티드 | 앤지오포이에틴-2에 대한 항체 및 그의 용도 |
WO2006118617A2 (en) | 2004-12-23 | 2006-11-09 | Chlorogen, Inc. | EXPRESSING TGF-β PROTEINS IN PLANT PLASTIDS |
ES2395953T3 (es) | 2005-01-26 | 2013-02-18 | Amgen Fremont Inc. | Anticuerpos frente a interleucina-1 beta |
PL1853718T3 (pl) | 2005-02-15 | 2016-01-29 | Univ Duke | Przeciwciała anty-CD19 i zastosowania w onkologii |
AU2006216291B2 (en) | 2005-02-27 | 2011-01-27 | Institute For Antibodies Co., Ltd. | Anti-IgSF4 antibody and utilization of the same |
JP5164829B2 (ja) | 2005-03-24 | 2013-03-21 | トロンボジェニクス・ナムローゼ・フエンノートシャップ | 新規な抗plgf抗体 |
JP5011277B2 (ja) | 2005-04-06 | 2012-08-29 | アイビーシー・ファーマシューティカルズ・インコーポレーテッド | ホモダイマー、ホモテトラマーまたはダイマーのダイマーのからなる安定に連結された複合体を発生させるための方法および使用 |
TW200724548A (en) | 2005-04-25 | 2007-07-01 | Pfizer | Antibodies to myostatin |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
JP5047947B2 (ja) | 2005-05-05 | 2012-10-10 | デューク ユニバーシティ | 自己免疫疾患のための抗cd19抗体治療 |
UA96416C2 (uk) | 2005-05-27 | 2011-11-10 | Байоджэн Айдэк Ма Инк. | Антитіло, яке зв'язується з tweak людини |
ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
TW200738256A (en) | 2005-06-24 | 2007-10-16 | Novozymes As | Lipases for pharmaceutical use |
EP1896073B1 (en) | 2005-06-30 | 2013-03-06 | Janssen Biotech, Inc. | Anti-il-23 antibodies, compositions, methods and uses |
DK2239327T3 (en) | 2005-08-11 | 2015-05-18 | Synthetic Genomics Inc | A method for in vitro recombination |
US20090215992A1 (en) | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
CN101370525B (zh) | 2005-08-19 | 2013-09-18 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
KR101460932B1 (ko) | 2005-08-26 | 2014-11-12 | 로슈 글리카트 아게 | 변형된 세포 신호 활성을 가진 개질된 항원 결합 분자 |
US7906116B2 (en) | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
EP1933714B1 (en) | 2005-09-21 | 2020-03-18 | The Regents of The University of California | Systems and compositions for local imaging and treatment of pain |
AU2006294870B2 (en) | 2005-09-23 | 2011-08-04 | WRAIR, a U.S Army Research institution under the United States Government, as represented by the Secretary of the Army | Antibodies with simultaneous subsite specificities to protein and lipid epitopes |
EP3770174A1 (en) | 2005-10-11 | 2021-01-27 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
WO2007048849A1 (en) | 2005-10-28 | 2007-05-03 | Novo Nordisk A/S | Fusion proteins that bind effector lymphocytes and target cells |
UA96139C2 (uk) | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
PE20070684A1 (es) | 2005-11-14 | 2007-08-06 | Amgen Inc | MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP |
ES2541302T3 (es) | 2005-11-18 | 2015-07-17 | Glenmark Pharmaceuticals S.A. | Anticuerpos anti-integrina alfa2 y sus usos |
CA2627446A1 (en) | 2005-11-21 | 2007-05-31 | Laboratoires Serono S.A. | Compositions and methods of producing hybrid antigen binding molecules and uses thereof |
CN117903302A (zh) | 2005-11-30 | 2024-04-19 | Abbvie 公司 | 抗-Aβ球聚体抗体,其相关产品,生产所述抗体的方法,所述抗体的应用以及使用方法 |
ATE552853T1 (de) | 2005-12-13 | 2012-04-15 | Medimmune Ltd | Proteine die spezifisch insulin-ähnliche wachstumsfaktoren binden, und deren anwendungen |
EP1981541A4 (en) | 2006-01-23 | 2011-09-28 | Errico Joseph P | METHODS AND COMPOSITIONS FOR DEVELOPING A TARGET MEDICINE |
US8377691B2 (en) | 2006-01-26 | 2013-02-19 | Integral Molecular, Inc. | Lipoparticles comprising ion channels, methods of making and using the same |
CN101374864A (zh) * | 2006-01-31 | 2009-02-25 | 诺瓦提斯公司 | 用于靶向癌症的il-17拮抗性抗体 |
US20070207171A1 (en) | 2006-03-01 | 2007-09-06 | Cerus Corporation | Engineered listeria and methods of use thereof |
JP5374359B2 (ja) | 2006-03-17 | 2013-12-25 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 安定化されたポリペプチド化合物 |
BRPI0708998A2 (pt) | 2006-03-21 | 2011-06-21 | Wyeth Corp | anticorpo que se liga especificamente ao rage; anticorpo quimérico ou um fragmento de ligação rage do mesmo; anticorpo humanizado ou um fragmento de ligação rage do mesmo; anticorpo humanizado que se liga especificamente ao rage ou um fragmento de ligação rage do mesmo; anticorpo que se liga especificamente ao rage e bloqueia a ligação de um parceiro corporal rage; ácido nucléico isolado; método de tratamento de um indivìduo que tem uma doença ou transtorno relacionado com rage; método de tratamento de sepse ou choque séptico em um indivìduo humano; método de tratamento de listeriose sistêmica em um indivìduo humano; e método de inibir a ligação de um parceiro de ligação rage (rage-bp), o rage em um indivìduo mamìfero |
AR060070A1 (es) | 2006-03-24 | 2008-05-21 | Merck Patent Gmbh | Dominios proteicos heterodimericos obtenidos por ingenieria |
EA200802061A1 (ru) | 2006-03-28 | 2009-04-28 | Байоджен Айдек Эмэй Инк. | Антитело или его фрагмент, специфично связывающееся с рецептором 1 инсулиноподобного фактора роста (igf-r1) (варианты), композиция на его основе, полинуклеотид, кодирующий вариабельную область антитела (варианты), содержащие полинуклеотид композиция (варианты) и вектор, содержащая вектор клетка-хозяин (варианты), способ продуцирования антитела или его фрагмента (варианты) и способ лечения гиперпролиферативного заболевания у животного организма |
US20070232556A1 (en) | 2006-03-31 | 2007-10-04 | Montine Thomas J | Methods and compositions for the treatment of neurological diseases and disorders |
EP2010213A4 (en) | 2006-04-10 | 2010-08-11 | Abbott Biotech Ltd | USE AND COMPOSITIONS FOR THE TREATMENT OF JUVENIL RHEUMATOID ARTHRITIS |
KR20080109093A (ko) | 2006-04-14 | 2008-12-16 | 노파르티스 아게 | 안과 장애 치료를 위한 il-1 항체의 용도 |
NZ571757A (en) | 2006-04-21 | 2012-01-12 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer |
WO2007124019A2 (en) | 2006-04-21 | 2007-11-01 | Gtc Biotherapeutics, Inc. | Methods and products related to the transfer of molecules from blood to the mammary gland |
US20070254338A1 (en) | 2006-04-24 | 2007-11-01 | Amgen Inc. | Method for making recombinant protein using complementation dependent DHFR mutants |
US20080118978A1 (en) | 2006-04-28 | 2008-05-22 | Takashi Sato | Anti-tumor agent |
CN101058609B (zh) | 2006-05-26 | 2011-04-13 | 神州细胞工程有限公司 | 人源抗体及其表达 |
AR061170A1 (es) | 2006-06-02 | 2008-08-06 | Aveo Pharmaceuticals Inc | Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf) |
WO2008060705A2 (en) | 2006-06-06 | 2008-05-22 | Genentech, Inc. | Anti-dll4 antibodies and methods using same |
KR20090016762A (ko) | 2006-06-06 | 2009-02-17 | 제넨테크, 인크. | 혈관 발달을 조정하기 위한 조성물 및 방법 |
CN1884517B (zh) | 2006-06-08 | 2010-06-30 | 武汉禾元生物科技有限公司 | 利用谷物非储藏蛋白为融合载体在胚乳表达多肽的方法及应用 |
WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
ES2427924T3 (es) | 2006-06-30 | 2013-11-04 | Merck Sharp & Dohme Corp. | Biomarcador IGFBP2 |
US20080081379A1 (en) | 2006-07-13 | 2008-04-03 | Sigler Gerald F | Homogeneous double receptor agglutination assay for immunosuppressant drugs |
WO2008011348A2 (en) | 2006-07-14 | 2008-01-24 | Ac Immune S.A. | Humanized antibody against amyloid beta |
US7592156B2 (en) | 2006-07-20 | 2009-09-22 | Wyeth | Synthetic dog/human chimeric C-C chemokine receptor 2B |
US7883855B2 (en) | 2006-07-21 | 2011-02-08 | Abbott Laboratories | Immunosuppressant drug extraction reagent for immunoassays |
WO2008021974A1 (en) | 2006-08-11 | 2008-02-21 | Monsanto Technology Llc | Production of high tryptophan maize by chloroplast targeted expression of anthranilate synthase |
ES2457072T3 (es) | 2006-08-14 | 2014-04-24 | Xencor, Inc. | Anticuerpos optimizados que seleccionan como diana CD19 |
ES2902063T3 (es) | 2006-09-08 | 2022-03-24 | Abbvie Bahamas Ltd | Proteínas de unión a interleucina-13 |
US20080075690A1 (en) | 2006-09-22 | 2008-03-27 | Mark Douglas Howell | Method for enhancing immune responses in mammals |
BRPI0717431A2 (pt) | 2006-09-29 | 2013-11-12 | Oncomed Pharm Inc | Composições e métodos de diagnóstico e tratamento do câncer |
US20080102475A1 (en) | 2006-10-13 | 2008-05-01 | Zhengyan Kan | Alternatively spliced isoform of phosphodiesterase 4B (PDE4B) |
PL2907827T3 (pl) | 2006-11-02 | 2019-03-29 | Genentech, Inc. | Humanizowane przeciwciała przeciw czynnikowi D i ich zastosowanie |
WO2008079326A2 (en) | 2006-12-20 | 2008-07-03 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
DE602008004296D1 (de) | 2007-02-14 | 2011-02-17 | Vaccinex Inc | Humanisierte anti-cd100-antikörper |
EP2647388A1 (en) | 2007-02-16 | 2013-10-09 | Merrimack Pharmaceuticals, Inc. | Antibodies Against ERBB3 and Uses Thereof |
CA2681530C (en) | 2007-03-22 | 2017-03-28 | Biogen Idec Ma Inc. | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 |
US7906293B2 (en) | 2007-04-09 | 2011-03-15 | Abbott Laboratories | Acridinium phenyl esters useful in the analysis of biological |
WO2008131376A2 (en) | 2007-04-23 | 2008-10-30 | Wyeth | Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
GB0708002D0 (en) | 2007-04-25 | 2007-06-06 | Univ Sheffield | Antibodies |
EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
DK2164992T3 (en) | 2007-05-30 | 2016-08-15 | Lpath Inc | COMPOSITIONS AND METHODS FOR BONDING OF LYTHOPHOSPHATIC ACID |
EP2167961A4 (en) | 2007-06-27 | 2010-07-21 | Univ Leland Stanford Junior | BETA2-MICROGLOBULIN AND C-REACTIVE PROTEIN (CRP) AS BIOMARKERS FOR PERIPHERAL ARTERY DISEASE |
AU2008282218A1 (en) | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
RU2010107994A (ru) | 2007-08-08 | 2011-09-20 | Эбботт Лэборетриз (Us) | Композиции и способы кристаллизации антител |
ES2628395T3 (es) | 2007-08-15 | 2017-08-02 | Bayer Pharma Aktiengesellschaft | Anticuerpo regulado por proteasa |
CA2702611A1 (en) | 2007-10-19 | 2009-04-23 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
WO2009077993A2 (en) | 2007-12-17 | 2009-06-25 | Pfizer Limited | Treatment of interstitial cystitis |
PL2235064T3 (pl) | 2008-01-07 | 2016-06-30 | Amgen Inc | Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych |
AU2009206089B2 (en) | 2008-01-15 | 2014-08-28 | Abbvie Inc. | Improved mammalian expression vectors and uses thereof |
US7605603B1 (en) * | 2008-02-29 | 2009-10-20 | Altera Corporation | User-accessible freeze-logic for dynamic power reduction and associated methods |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
JP5470817B2 (ja) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | 電池用電極およびこれを用いた電池、並びにその製造方法 |
US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
SG190572A1 (en) | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
US8323651B2 (en) | 2008-05-09 | 2012-12-04 | Abbott Laboratories | Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof |
KR20110016959A (ko) | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
US8741287B2 (en) | 2008-06-18 | 2014-06-03 | Abbott Laboratories | PlGF-1 assay and kits and components thereof |
RU2011104348A (ru) * | 2008-07-08 | 2012-08-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение |
EP2310049A4 (en) | 2008-07-08 | 2013-06-26 | Abbvie Inc | PROSTAGLANDIN E2 BINDING PROTEINS AND USES THEREOF |
US9273136B2 (en) | 2008-08-04 | 2016-03-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fully human anti-human NKG2D monoclonal antibodies |
EP2342562B1 (en) | 2008-09-30 | 2013-09-18 | AbbVie Inc. | Improved method of rna display |
JP6034564B2 (ja) | 2008-11-13 | 2016-11-30 | イースタン バージニア メディカル スクール | ナノ秒パルス電界による、ヒト血小板の活性化および凝集方法ならびに血小板ゲルの形成方法 |
AU2009322236B2 (en) | 2008-12-04 | 2013-11-07 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
PE20160651A1 (es) * | 2009-03-05 | 2016-07-24 | Abbvie Inc | Proteinas de union a il-17 |
MX2011011670A (es) | 2009-05-01 | 2011-11-18 | Abbott Lab | Inmunoglobulinas de dominio variable dual y usos de las mismas. |
BRPI1012193A2 (pt) | 2009-05-01 | 2019-09-24 | Abbott Lab | imunoglobulinas de domínio variável duplo e usos das mesmas |
UY32808A (es) | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
NZ598524A (en) | 2009-08-29 | 2014-06-27 | Abbvie Inc | Therapeutic dll4 binding proteins |
IN2012DN02737A (es) | 2009-09-01 | 2015-09-11 | Abbott Lab | |
US20110172398A1 (en) | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
WO2011047262A2 (en) | 2009-10-15 | 2011-04-21 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
US8398966B2 (en) | 2009-10-15 | 2013-03-19 | Abbvie Inc. | IL-1 binding proteins |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
CN105037543B (zh) | 2010-03-02 | 2020-11-03 | Abbvie 公司 | 治疗性dll4结合蛋白 |
LT2571532T (lt) | 2010-05-14 | 2017-08-10 | Abbvie Inc. | Il-1 surišantys baltymai |
JP2013539353A (ja) | 2010-06-24 | 2013-10-24 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリンおよびその使用 |
UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
AR082461A1 (es) | 2010-08-03 | 2012-12-12 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
KR20130139884A (ko) | 2010-08-26 | 2013-12-23 | 애브비 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
EP2635694A4 (en) | 2010-11-02 | 2015-11-11 | Abbott Lab | VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF |
WO2012061558A2 (en) | 2010-11-04 | 2012-05-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
EP2915818A3 (en) | 2011-12-30 | 2015-11-11 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
CA2861610A1 (en) | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual specific binding proteins directed against il-13 and/or il-17 |
CN104245733A (zh) | 2011-12-30 | 2014-12-24 | 艾伯维公司 | 针对受体的双重可变结构域免疫球蛋白 |
KR20210111353A (ko) | 2012-11-01 | 2021-09-10 | 애브비 인코포레이티드 | 항-vegf/dll4 이원 가변 도메인 면역글로불린 및 이의 용도 |
US20140213772A1 (en) | 2012-12-28 | 2014-07-31 | Abbvie, Inc. | Cross-over dual variable domain immunoglobulin constructs |
JP6136279B2 (ja) | 2013-01-15 | 2017-05-31 | 株式会社ジェイテクト | 転がり軸受装置 |
RU2015143833A (ru) | 2013-03-15 | 2017-04-21 | Эббви Инк. | СВЯЗЫВАЮЩИЕ БЕЛКИ С ДВОЙНОЙ СПЕЦИФИЧНОСТЬЮ, НАПРАВЛЕННЫЕ ПРОТИВ TNFα |
JP2016522793A (ja) | 2013-03-15 | 2016-08-04 | アッヴィ・インコーポレイテッド | IL−1βおよび/またはIL−17に対して指向された二重特異的結合タンパク質 |
TWI503850B (zh) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | 過電流保護元件 |
TWI510996B (zh) | 2013-10-03 | 2015-12-01 | Acer Inc | 控制觸控面板的方法以及使用該方法的可攜式電腦 |
US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
-
2009
- 2009-06-03 AR ARP090101994A patent/AR072001A1/es not_active Application Discontinuation
- 2009-06-03 NZ NZ589434A patent/NZ589434A/xx not_active IP Right Cessation
- 2009-06-03 JP JP2011512617A patent/JP2011523853A/ja not_active Ceased
- 2009-06-03 US US12/477,711 patent/US9035027B2/en active Active
- 2009-06-03 AU AU2009256250A patent/AU2009256250B2/en not_active Ceased
- 2009-06-03 MX MX2010013239A patent/MX2010013239A/es active IP Right Grant
- 2009-06-03 UY UY0001031862A patent/UY31862A/es not_active Application Discontinuation
- 2009-06-03 EP EP09759348A patent/EP2297209A4/en not_active Withdrawn
- 2009-06-03 KR KR1020107029457A patent/KR20110016958A/ko not_active Application Discontinuation
- 2009-06-03 PE PE2009000768A patent/PE20100092A1/es not_active Application Discontinuation
- 2009-06-03 CN CN2009801297830A patent/CN102112495A/zh active Pending
- 2009-06-03 CA CA2726087A patent/CA2726087A1/en not_active Abandoned
- 2009-06-03 TW TW098118450A patent/TW201008580A/zh unknown
- 2009-06-03 SG SG2013042916A patent/SG191639A1/en unknown
- 2009-06-03 RU RU2010153580/10A patent/RU2010153580A/ru not_active Application Discontinuation
- 2009-06-03 BR BRPI0913406A patent/BRPI0913406A2/pt not_active IP Right Cessation
- 2009-06-03 EP EP15189272.6A patent/EP3002299A1/en not_active Withdrawn
- 2009-06-03 WO PCT/US2009/046137 patent/WO2009149189A2/en active Application Filing
-
2010
- 2010-11-23 IL IL209529A patent/IL209529A0/en unknown
- 2010-11-29 EC EC2010010644A patent/ECSP10010644A/es unknown
- 2010-11-29 ZA ZA2010/08560A patent/ZA201008560B/en unknown
- 2010-11-30 CO CO10150956A patent/CO6331347A2/es not_active Application Discontinuation
- 2010-11-30 DO DO2010000368A patent/DOP2010000368A/es unknown
- 2010-12-03 NO NO20101692A patent/NO20101692A1/no not_active Application Discontinuation
- 2010-12-09 CR CR11837A patent/CR11837A/es not_active Application Discontinuation
- 2010-12-10 CL CL2010001427A patent/CL2010001427A1/es unknown
-
2014
- 2014-04-08 US US14/248,223 patent/US20140335014A1/en not_active Abandoned
-
2015
- 2015-04-15 US US14/687,392 patent/US20150315283A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2297209A4 (en) | 2012-08-01 |
SG191639A1 (en) | 2013-07-31 |
US9035027B2 (en) | 2015-05-19 |
EP3002299A1 (en) | 2016-04-06 |
WO2009149189A2 (en) | 2009-12-10 |
CO6331347A2 (es) | 2011-10-20 |
CL2010001427A1 (es) | 2011-07-15 |
AU2009256250A1 (en) | 2009-12-10 |
WO2009149189A3 (en) | 2010-03-04 |
US20090311253A1 (en) | 2009-12-17 |
CA2726087A1 (en) | 2009-12-10 |
TW201008580A (en) | 2010-03-01 |
KR20110016958A (ko) | 2011-02-18 |
DOP2010000368A (es) | 2011-02-15 |
EP2297209A2 (en) | 2011-03-23 |
NZ589434A (en) | 2012-11-30 |
NO20101692A1 (no) | 2011-03-03 |
ECSP10010644A (es) | 2011-02-28 |
CR11837A (es) | 2011-01-12 |
AR072001A1 (es) | 2010-07-28 |
US20140335014A1 (en) | 2014-11-13 |
UY31862A (es) | 2010-01-05 |
AU2009256250B2 (en) | 2013-05-30 |
RU2010153580A (ru) | 2012-07-20 |
JP2011523853A (ja) | 2011-08-25 |
ZA201008560B (en) | 2014-05-28 |
MX2010013239A (es) | 2011-02-24 |
US20150315283A1 (en) | 2015-11-05 |
BRPI0913406A2 (pt) | 2018-01-09 |
CN102112495A (zh) | 2011-06-29 |
IL209529A0 (en) | 2011-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20100092A1 (es) | Inmunoglobulina con dominio variable dual y usos de la misma | |
PE20121530A1 (es) | Inmunoglobulinas con dominio variable dual | |
PE20121531A1 (es) | Inmunoglobulinas con dominio variable dual | |
PE20121543A1 (es) | Inmunoglobulinas con dominio variable dual | |
PE20100054A1 (es) | Inmunoglobulina con dominio variable dual | |
PE20140229A1 (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
PE20130205A1 (es) | Proteinas de union a il-1 | |
PE20131413A1 (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
AR076508A1 (es) | Inmunoglobulina con dominio variable dual y usos de la misma | |
PE20140633A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
PE20131412A1 (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
PE20130614A1 (es) | Inmunoglobulinas con dominio variable dual y su uso | |
PE20091845A1 (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
UA106607C2 (uk) | Білки специфічного зв'язування і їх застосування | |
NZ611324A (en) | Il-17 binding proteins | |
CL2011000308A1 (es) | Anticuerpo monoclonal que se une al gen 3 de la activacion linfocitaria (lag-3) humana; composicion que comprende dicho anticuerpo; molecula de acido nucleico que lo codifica; vector de expresion y celula huesped que lo comprende; metodo de preparacion; y su uso para estimular la respuesta inmune. | |
AR091069A1 (es) | Proteinas de union a antigeno dirigidas contra el receptor st2 | |
AR080793A1 (es) | Anticuerpos biespecificos | |
BRPI0914319B8 (pt) | imunoligante que se liga especificamente ao tnf alfa humano e composição | |
WO2008121615A3 (en) | Antibody formulation | |
CL2012002095A1 (es) | Polipéptido de unión biparatópico que comprende un primer dominio variable individual de inmunoglobulina (ig) que se une específicamente a un primer epítopo del péptido ß-amiloide (ßa) y un segundo dominio variable de ig que se une específicamente a un segundo epítopo del ßa, donde dichos epítopos del ßa no son idénticos; ácido nucleico que lo codifica; vector; célula hospedera; composición farmacéutica; método de preparación; y su uso en el tratamiento y/o prevención de depósitos del ßa | |
AR077088A1 (es) | Proteinas biespecificas de union a antigeno | |
EP2987806A3 (en) | Modified single variable domain antibodies with reduced binding to anti-drug-antibodies | |
RU2014144143A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток | |
EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |